No Data
No Data
Medigene AG Adjusts 2024 Financial Guidance Amid Milestone Payment Delay
Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers
Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment
Medigene AG Reports Financial Results and Business Update for Q3 2024
Medigene AG Expands Protection of Its KRAS Library With Filing of New Patent Application Supporting MDG2021
Press Release: Medigene Announces U.S. FDA Clearance of IND Application for MDG1015, a First-in-Class, Third Generation T Cell Receptor Engineered T Cell (TCR-T) Therapy for Multiple Solid Tumor Indications